DISCOUNT ZERTIFIKAT - ROCHE GS Share Price

Certificat

DE000VU9B9R3

Delayed Deutsche Boerse AG 08:10:14 20/06/2024 pm IST
226 EUR -0.50% Intraday chart for DISCOUNT ZERTIFIKAT - ROCHE GS
Current month+5.16%
1 month+5.21%
Date Price Change
20/24/20 226 -0.50%
19/24/19 227.1 +0.11%
18/24/18 226.9 +0.79%
17/24/17 225.1 -0.48%
14/24/14 226.2 +0.93%

Delayed Quote Deutsche Boerse AG

Last update June 20, 2024 at 08:10 pm IST

More quotes

Static data

Product typeCertificats Discount
Buy / SellCALL
Underlying ROCHE HOLDING AG
IssuerLogo Issuer Vontobel Vontobel
WKN VU9B9R
ISINDE000VU9B9R3
Date issued 07/07/2023
Cap 220 CHF
Last trading day 20/12/2024
Maturity 20/12/2024 (183 Days)
Parity 1 : 1
Emission price 212.4
Emission volume N/A
Payment day 31/12/2024
Bonus-
Settlement les deux
Currency EUR

Technical Indicators

Discount (ask) 0.000000 %
Sideways yield 0.000000 %
Sideways yield pa 0.000000 %
Outperformance point- CHF
Break even 0.000000 €
Highest since issue 227.2
Lowest since issue 209.9
Spread 2.63
Spread %1.15%
Distance Cap 30 CHF
Distance Cap %+12.00%
Max. earning-
Max. earning % 0.000000 %

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
249.8 CHF
Average target price
278.1 CHF
Spread / Average Target
+11.31%
Consensus